Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
about
Immunological effect of local ablation combined with immunotherapy on solid malignancies.Clinical applications of PD-L1 bioassays for cancer immunotherapy.High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodesImmunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival.Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor TherapyUpdate on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer.The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.Interlaboratory-concordance of PD-L1 immunohistochemistry for non-small cell lung cancer.Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors.Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis.The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions.Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.The importance for immunoregulation for long-term cancer control.New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.Atezolizumab for the treatment of non-small cell lung cancer.Combining radiotherapy with immunotherapy: the past, the present and the future.Cancer Immunotherapies: Are They as Effective in the Elderly?Immune checkpoint inhibitors in lung cancer: an update.Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future.Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer.Correlation of immune phenotype with IDH mutation in diffuse glioma.Immunogenomics: using genomics to personalize cancer immunotherapy.Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.Targeting the PD-1 pathway in pediatric solid tumors and brain tumors.The next generation of immunotherapy: keeping lung cancer in check.Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC.Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer.Prospects and progress of atezolizumab in non-small cell lung cancer.The safety of second-line treatment options for non-small cell lung cancer.
P2860
Q30354580-91FEE7B5-AEBF-46CF-BAB5-73F84AC6F2A4Q33702815-62D0519F-CCA1-4A2C-80F3-E7C4CA92884AQ33718731-B63F304D-69FE-46AC-B4BF-A5B633DB5E9AQ33819820-6BD3748F-BE64-4418-8777-9934A9380E7DQ33876861-8B98B371-623A-431F-A657-11AE4A008D19Q33912075-3D40068C-B02F-4A25-BEDA-DD878B53DEF1Q36305457-EF6DE649-26E1-4E58-BCD1-3C8E6CD64B8BQ36356608-22042298-1465-40A4-80D5-1A59BAD86035Q36400381-8C08BAC7-D940-4F07-83F9-BD228BD3F355Q37629874-D5319A4C-700A-42E5-95A7-112549291534Q37739214-2F3742F3-19F4-411B-ABC0-440C23949228Q38401891-CBEF54D5-958D-46A8-A329-22304A757601Q38603546-4F36C6F2-73F0-4FDF-A733-A2C8A1DEA07DQ38604723-8D6E868F-2E63-4E9E-9EBE-CE9DF9B43A8AQ38621228-D7BDB501-5AE8-4BDF-8E15-B84F406300BEQ38630412-C0B51D2C-7A7C-43D8-9F08-219821B9B5A7Q38635259-C3FEF493-052B-4C0D-8684-7D563211FB35Q38640845-908096AE-CE72-4398-A3F7-585A162F7A83Q38647002-E15E0B3E-6BD2-48A2-AB6C-9349ACAC5A2EQ38648979-FBCBA739-576D-4350-8303-A37DBBAF12B2Q38670719-A38FB66B-7187-409C-850D-F262495BC290Q38672084-C637B33A-770B-4748-B49A-8756901B256BQ38675969-D5D63444-FF47-452D-B6EA-83ADF4626257Q38679418-9E607FD2-7FF1-4654-B84E-DFB977FBE078Q38679662-3B76E19A-0C88-4D94-9DA1-28C34C18D7CAQ38686642-2F87BB14-65FA-4D50-85D1-3AEEC96194E1Q38687631-85802AB8-E3E8-4830-87A0-DF672FF45252Q38689104-39BC9607-7457-404A-A3A2-BB1B491BE4B9Q38720801-07F6B778-ED66-49A2-B3BF-131DCDCBF4D6Q38752269-1917788A-C261-4BE8-BA72-9FDA70342790Q38769610-12A27BF2-403E-40AE-9375-0CA8ABEB2008Q38771020-40D904F1-C858-448A-95B6-8761D38A0279Q38772744-A2F4EF12-1F83-4A8F-BE87-7454A07FEC2CQ38774624-AB9D2261-D085-4110-BC3D-33E13A3D14D5Q38819982-C383F6B9-0462-44B4-BB56-88D0D7CB4A97Q38824489-4AABCDC5-A234-4B62-AA25-8AF857E97723Q38840383-0F3A1E0A-ADD6-452B-BAD3-9641E46485CBQ38870763-18091547-1AF1-4AC6-872B-91D454AEB880Q38881814-D21A5FDB-B936-484D-BFED-CD567C795AB6Q39170310-F3291B9B-92A9-4C3B-BCE9-5E22AED7751A
P2860
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Atezolizumab versus docetaxel ...... e randomised controlled trial.
@en
type
label
Atezolizumab versus docetaxel ...... e randomised controlled trial.
@en
prefLabel
Atezolizumab versus docetaxel ...... e randomised controlled trial.
@en
P2093
P50
P921
P1433
P1476
Atezolizumab versus docetaxel ...... re randomised controlled trial
@en
P2093
Achim Rittmeyer
Alan Sandler
Carlos Barrios
Daniel Waterkamp
David R Gandara
Fabrice Barlesi
Fairooz Kabbinavar
Filippo De Marinis
Fortunato Ciardiello
Hande Turna
P304
P356
10.1016/S0140-6736(16)32517-X
P407
P577
2016-12-13T00:00:00Z